Free Seminar
Learn about the Swing Trading College with Larry Connors. Register now!
Make sure to visit www.streetinvesting.com to keep updated and signup for free with no credit card for market reports and analytical plays.
Our research resources have been aimed towards the US Large Caps and the various prospective companies therein Genta Incorporated was among those that we have been closely examining due to their recent news and trading patterns.
March 7, 2008 Genta Incorporated (Nasdaq: GNTA)announced the Company has entered into an exclusive worldwide licensing agreement with Daiichi Sankyo Company, Limited (TYO: 4568) for the development and commercialization of tesetaxel (formerly known as DJ-927). As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes, such as paclitaxel (Taxol ) and docetaxel (Taxotere ; sanofi aventis). Moreover, unlike other oral taxanes that are currently in clinical development, nerve damage has not been a prominent side effect of tesetaxel. Preclinical studies also show that tesetaxel does not share resistance mechanisms that are associated with other taxanes. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity.
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Streetinvesting.com will continue to follow the progress of this company following their most recent news announcement. Visit www.streetinvesting.com and signup free for our financial market services.
At Streetinvesting.com, we bring our knowledge of the marketplace and investment opportunities directly to our subscribers. As an aggressive-growth research company, our strength and goal is bringing distinctive trading opportunities and investment philosophies to investors seeking a different and unique approach to investment ideas. That's our goal. That's what we do. We are "The Word on the Street".
Let us become your number one portal for research and information on the global markets.
To continue with the more in-depth analysis, please visit www.streetinvesting.com for a complimentary subscription to access this report and other related articles. Please note that membership does not require credit card information.
All material herein was prepared by Streetinvesting.com, (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Streetinvesting.com's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.
CONTACT: Streetinvesting.com WWW: http://www.streetinvesting.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
